Regeneron reports first quarter 2021 financial and operating results

Tarrytown, n.y., may 6, 2021 /prnewswire/ -- first quarter 2021 revenues increased 38% to $2.53 billion versus first quarter 2020; revenues excluding regen-cov tm(1) increased 20% first quarter 2021 eylea® u.s. net sales increased 15% to $1.35 billion versus first quarter 2020 first quarter 2021 dupixent® global net sales (2) , which are recorded by sanofi, increased 48% to $1.26 billion versus first quarter 2020 first quarter 2021 gaap diluted eps was $10.09 and non-gaap diluted eps (1) was $9.89 three fda approvals received: libtayo® for first-line advanced non-small cell lung cancer (nsclc) and advanced basal cell carcinoma (bcc), and evkeeza tm for homozygous familial hypercholesterolemia (hofh) positive data reported from phase 3 trials with regen-cov used to treat and prevent covid-19 regeneron pharmaceuticals, inc. (nasdaq: regn) today announced financial results for the first quarter of 2021 and provided a business update.
REGN Ratings Summary
REGN Quant Ranking